Market overview
The global implantable drug delivery market is worth USD 12.9 bn in 2026 and is forecast to reach USD 27.3 bn by 2036, growing at a 7.8% CAGR. United States is the largest country market and Drug-eluting implants and rods is the largest by product segment.
| Scope | Implantable drug delivery systems: implanted pumps, drug-eluting implants, depot rods, intrauterine and contraceptive implants and long-acting depot devices delivering a drug over weeks to years. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 12.0 bn |
| Value 2026 | USD 12.9 bn |
| Value 2036 | USD 27.3 bn |
| CAGR 2026-2036 | 7.8% |
| Volume 2026 | 96.0 million units |
| Volume 2036 | 188 million units |
| Average price 2026 | USD 134 per unit |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Implantable Drug Delivery market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 12.9 bn |
| 2027 | USD 13.9 bn |
| 2028 | USD 15.0 bn |
| 2029 | USD 16.2 bn |
| 2030 | USD 17.4 bn |
| 2031 | USD 18.8 bn |
| 2032 | USD 20.2 bn |
| 2033 | USD 21.8 bn |
| 2034 | USD 23.5 bn |
| 2035 | USD 25.4 bn |
| 2036 | USD 27.3 bn |
Implantable Drug Delivery market segmentation
By product
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Implantable pumps | 18.0% | 13.6% | USD 2.3 bn | 4.8% |
| Drug-eluting implants and rods | 40.0% | 43.9% | USD 5.2 bn | 8.8% |
| Intrauterine systems | 24.0% | 20.9% | USD 3.1 bn | 6.3% |
| Long-acting depots | 18.0% | 21.6% | USD 2.3 bn | 9.8% |
By use
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Contraception and hormonal | 32.0% | 27.4% | USD 4.1 bn | 6.1% |
| Oncology | 22.0% | 21.7% | USD 2.8 bn | 7.6% |
| Pain and CNS | 22.0% | 23.8% | USD 2.8 bn | 8.6% |
| Ophthalmic, dental and other | 24.0% | 27.2% | USD 3.1 bn | 9.1% |
By material
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Biodegradable polymers | 40.0% | 42.0% | USD 5.2 bn | 8.3% |
| Silicone | 26.0% | 22.0% | USD 3.4 bn | 6.0% |
| Titanium and metal alloys | 20.0% | 20.0% | USD 2.6 bn | 7.8% |
| Ceramic and composite | 14.0% | 16.0% | USD 1.8 bn | 9.2% |
By release duration
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Short, under six months | 26.0% | 22.0% | USD 3.4 bn | 6.0% |
| Medium, six to twelve months | 34.0% | 32.0% | USD 4.4 bn | 7.2% |
| Long, over twelve months | 40.0% | 46.0% | USD 5.2 bn | 9.3% |
By end user
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Hospitals | 52.0% | 48.0% | USD 6.7 bn | 6.9% |
| Specialty clinics | 26.0% | 28.0% | USD 3.4 bn | 8.6% |
| Ambulatory centres | 22.0% | 24.0% | USD 2.8 bn | 8.7% |
Top 25 countries for implantable drug delivery by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 82.5% of 2026 revenue and the 25 countries below together hold 95.1%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 5.7 bn | 44.0% | USD 12.0 bn | 7.8% |
| 2 | Germany | USD 774 mn | 6.0% | USD 1.5 bn | 6.9% |
| 3 | China | USD 774 mn | 6.0% | USD 1.6 bn | 7.8% |
| 4 | Japan | USD 645 mn | 5.0% | USD 1.2 bn | 6.2% |
| 5 | United Kingdom | USD 645 mn | 5.0% | USD 1.3 bn | 7.4% |
| 6 | France | USD 645 mn | 5.0% | USD 1.3 bn | 6.9% |
| 7 | Canada | USD 387 mn | 3.0% | USD 793 mn | 7.4% |
| 8 | Italy | USD 387 mn | 3.0% | USD 738 mn | 6.7% |
| 9 | Brazil | USD 387 mn | 3.0% | USD 930 mn | 9.2% |
| 10 | India | USD 322 mn | 2.5% | USD 930 mn | 11.2% |
| 11 | Spain | USD 186 mn | 1.4% | USD 391 mn | 7.7% |
| 12 | South Korea | USD 163 mn | 1.3% | USD 342 mn | 7.7% |
| 13 | Australia | USD 163 mn | 1.3% | USD 342 mn | 7.7% |
| 14 | Netherlands | USD 116 mn | 0.9% | USD 243 mn | 7.7% |
| 15 | Mexico | USD 116 mn | 0.9% | USD 306 mn | 10.2% |
| 16 | Switzerland | USD 116 mn | 0.9% | USD 243 mn | 7.7% |
| 17 | Turkey | USD 116 mn | 0.9% | USD 306 mn | 10.2% |
| 18 | Russia | USD 93 mn | 0.7% | USD 194 mn | 7.7% |
| 19 | Belgium | USD 93 mn | 0.7% | USD 194 mn | 7.7% |
| 20 | Sweden | USD 93 mn | 0.7% | USD 194 mn | 7.7% |
| 21 | Taiwan | USD 93 mn | 0.7% | USD 194 mn | 7.7% |
| 22 | Saudi Arabia | USD 70 mn | 0.5% | USD 183 mn | 10.2% |
| 23 | Poland | USD 70 mn | 0.5% | USD 148 mn | 7.8% |
| 24 | Ireland | USD 70 mn | 0.5% | USD 148 mn | 7.8% |
| 25 | Indonesia | USD 70 mn | 0.5% | USD 219 mn | 12.1% |
| Rest of world | USD 632 mn | 4.9% | USD 1.4 bn | 8.2% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Merck
- AstraZeneca
- Medtronic
- Bayer
- Abbott
- Organon
- AbbVie
Group 2: Regional and specialist players
- Indivior
- Camurus
- Alkermes
- Endo
- Ocular Therapeutix
Group 3: Emerging and niche players
- Flowonix
- Tolmar
- EyePoint Pharmaceuticals
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the implantable drug delivery market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 7.8% is calculated from the resulting values.
The market is divided by product, by use, by material, by release duration, by end user. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the implantable drug delivery market?
The global implantable drug delivery market is estimated at USD 12.0 bn in 2025 and USD 12.9 bn in 2026.
How fast will the implantable drug delivery market grow?
It is forecast to reach USD 27.3 bn by 2036, a compound annual growth rate of 7.8% from 2026, an increase of USD 14.4 bn.
Which country is the largest market for implantable drug delivery?
United States is the largest market by revenue at USD 5.7 bn in 2026, 44.0% of the global total. The three largest countries together hold 56.0%.
Which country is growing fastest?
Among the ten largest markets, India is growing fastest at 11.2% a year from 2026 to 2036.
Which implantable drug delivery segment is largest?
In the by product split, Drug-eluting implants and rods is the largest segment with 40.0% of 2026 revenue.
Who are the leading implantable drug delivery companies?
Global leaders include Merck, AstraZeneca, Medtronic, Bayer.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- ChromatographyUSD 12.6 bn · 6.0% CAGR
- RNA TherapeuticsUSD 13.4 bn · 18.0% CAGR
- Oligonucleotide TherapeuticsUSD 12.2 bn · 16.0% CAGR
- BioreactorUSD 13.7 bn · 10.0% CAGR
- RadiopharmaceuticalsUSD 12.1 bn · 12.5% CAGR
- Sterilization EquipmentUSD 11.7 bn · 6.0% CAGR
- Polymerase Chain ReactionUSD 11.6 bn · 6.5% CAGR
- Gene TherapyUSD 11.3 bn · 22.0% CAGR
← Impedance-based TEER Measurement System Implantable Tibial Neuromodulation →